Full Press Release Details
Game-Changing Technology for the Vaccine
and Therapeutic Biologics Business
Noble Financial Sixth Annual Equity Conference
This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees
of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. These
risks and uncertainties are discussed in our registration statement on file with the Securities and Exchange Commission. Unless required by law, the company undertakes no obligation to update publicly any forward-looking statements.
SAFE HARBOR STATEMENT
iBioLaunch Platform: Best Technology for New
Photo from Medicinenet.com
Traditional: Egg Technology
Some Flu Viruses Kill Eggs
Newer: Animal Cell Technology
Expensive Facilities
Contamination Concerns
iBioLaunch Technology
Rapid Production Cycles
Low Capital and COGs
No Animal/Human Pathogens
How Will iBio Create Shareholder Value?
High-Reward / Low-Risk Business Strategy
Broadly-sourced license revenue from defined product categories and
geographic regions corporations & governments
Value-enhancing early-stage development and co-development of products
Based on Disruptive iBioLaunch Platform Technology
Significant cost, time, safety and freedom-to-operate advantages
With Substantial Non-dilutive Financing
Over $70 million invested to date by government agencies and NGOs
$15 million pilot plant funded by U.S. government
New third-party commitments of $9.8 million for malaria, $4.4 million for H1N1
flu, and $5.3 million for anthrax-plague
External funding committed for two Phase 1 clinical trials 2010
A Substantial Business Opportunity:
Address International Needs for a Flexible and
Efficient Vaccine and Protein Manufacturing Platform
For generations, the United States has neglected to nurture
the technologies and systems needed to respond to
emergencies related to disease. Nowhere has this been more
evident than in the response to H1N1.
In six to nine months last year, the United States was able
to identify this new H1N1 virus, make vaccine and begin
distributing it, though in inadequate amounts. There
other disease to which our public health infrastructure could
respond anywhere near as quickly. For most new diseases,
the response time would be more like six to nine years.
Bob Graham & Jim Talent
Washington Post, January 4, 2010
Some analysts state that the
availability of more expensive,
state-of-the-art technological
new drugs fuel health
care spending not only because the
must be recouped by industry but
also because they generate
consumer demand for more intense,
costly services even if they are not
necessarily cost-effective.
Kaiser Family Foundation,
Congressional Budget Office
iBio s Proprietary Technology Enables Flexible and
Efficient Bio-Product Manufacturing
iBio Opportunities: Vaccines and Bio-defense
Corporations seek entry into lucrative vaccine markets
Nations seek regional autonomy for response to outbreaks and/or
iBio Opportunities: Therapeutic Proteins
Corporations seek to enter orphan medical markets
Corporations seek to launch bio-similar or bio-better products
Problem: Nations Are Poorly Prepared
Pandemics are global but political calculation to confront them is decidedly
local, Yanzhong Huang, YaleGlobal September 2009
Federal officials predicted that 160 million doses of H1N1 vaccine would be
available by October. In reality, there were fewer
than 30 million by that
time. Former U.S. Senators Bob Graham (D-Florida) and Jim Talent (R-
Missouri) wrote a scathing January 4 editorial blaming the shortage on
failure to nurture the technologies and systems needed. CSIS, January
Recent clinical, epidemiological and laboratory evidence suggests that the
impact of a pandemic caused by the current H5N1 strain would be similar to
pandemic, Michael T. Osterholm, Ph.D., MPH, Director,
Center for Infectious Disease Research and Policy, 2008
Problem: Bio-Terrorist Attacks Are Inevitable
December 29, 2004 Only a thin
wall of terrorist ignorance and
inexperience now protects us. -- Richard Danzig,
former Navy Secretary and Pentagon bioterrorism
CNN January 26, 2010
A commission set up to
assess national security measures on Tuesday
gave the U.S. government a failing grade in
improving response time to a biological attack.
Deployment of the iBioLaunch Platform to Produce Vaccines
for Pandemic Outbreaks and Combat Bioterrorism
Dramatic Improvement in Speed of Response
Days and weeks versus months
Location Flexibility and Practical Surge Capacity
Modular design and ease of tech transfer enable regional autonomy or
decentralized manufacturing
Scalability not constrained by biological limitations of fermentation and
cell culture methods, nor by equipment fabrication
Substantial Reduction in Capital Requirements for Scale
Less than $100 million